Michele BASTIDE

Dr. Michele BASTIDE

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2006 in Biochemical Society Transactions
Verified
Journal Article
Closed access
RBRégis Bordet
Régis Bordet
TOT. Ouk
T. Ouk
OPO. Petrault
O. Petrault
PGP. Gelé
P. Gelé
SGS. Gautier
S. Gautier
MBMichele BASTIDE
Michele BASTIDE
PPARs (peroxisome-proliferator-activated receptors) are ligand-activated transcriptional factor receptors belonging to the so-called nuclear receptor family. The three isoforms of PPAR (α, β/δ and γ) are involved in regulation of lipid or glucose metabolism. Beyond metabolic effects, PPARα and PPARγ activation also induces anti-inflammatory and antioxidant effects in different organs. These pleiotropic effects explain why PPARα or PPARγ activation has been tested as a neuroprotective agent in cerebral ischaemia. Fibrates and other non-fibrate PPARα activators as well as thiazolidinediones and other non-thiazolidinedione PPARγ agonists have been demonstrated to induce both preventive and acute neuroprotection. This neuroprotective effect involves both cerebral and vascular mechanisms. PPAR activation induces a decrease in neuronal death by prevention of oxidative or inflammatory mechanisms implicated in cerebral injury. PPARα activation induces also a vascular protection as demonstrated by prevention of post-ischaemic endothelial dysfunction. These vascular effects result from a decrease in oxidative stress and prevention of adhesion proteins, such as vascular cell adhesion molecule 1 or intercellular cell-adhesion molecule 1. Moreover, PPAR activation might be able to induce neurorepair and endothelium regeneration. Beyond neuroprotection in cerebral ischaemia, PPARs are also pertinent pharmacological targets to induce neuroprotection in chronic neurodegenerative diseases.

1 February 2000 in European Journal of Pharmacology
Verified
Journal Article
Closed access
FPFrançois Puisieux
François Puisieux
DDDominique Deplanque
Dominique Deplanque
QPQian Pu
Qian Pu
ESEvelyne Souil
Evelyne Souil
MBMichele BASTIDE
Michele BASTIDE
RBRégis Bordet
Régis Bordet

16 October 2017 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
CDC. Delattre
C. Delattre
CBC. Bournonville
C. Bournonville
FAF. Auger
F. Auger
RLR. Lopes
R. Lopes
CDC. Delmaire
C. Delmaire
MBMichele BASTIDE
Michele BASTIDE

1 October 2019 in Neurobiology of Disease
Verified
Journal Article
Open access
OPOlivier Pétrault
Olivier Pétrault
MPMaud Pétrault
Maud Pétrault
TOThavarak Ouk
Thavarak Ouk
RBRégis Bordet
Régis Bordet
VBVincent Bérézowski
Vincent Bérézowski
MBMichele BASTIDE
Michele BASTIDE
Midlife cognitive decline is now recognized as a factor of poor prognosis for late-life dementia. Although an epidemiological link has been suggested with high fat diet (HFD)-induced metabolic disorders, the effect of a long period of HFD on midlife cerebrovascular and cognitive functions remains unproven. A cohort of 216 young mice was fed with HFD up to middle age (12 months), and kinetically characterized for metabolic status, including weight, blood lipid profile, hepatic fat accumulation, glucose intolerance, and visceral adiposity. Metabolic disorders were evidenced from 3 months of HFD. Visual recognition memory and flexibility were significantly altered and associated to a visceral adiposity whereas spatial reference memory and working memory did not. Concomitantly, a progressive dysfunction of the vascular endothelium-dependent relaxation was detected in both middle cerebral artery and parenchymal arterioles, with consequences on the regulation of cerebral blood flow, but without any modification of the basal brain tissue MRI perfusion signal. Our data collection empowered us to stratify the mice according to their heterogeneous response to diet, and to propose a statistical prediction model for cognitive impairment, combining visceral adiposity and cerebral vasomotion in a diagnostic perspective of early neurological deficits.

1 November 2009 in Vascular Pharmacology
Verified
Journal Article
Closed access
TOThavarak Ouk
Thavarak Ouk
MLMaud Laprais
Maud Laprais
MBMichele BASTIDE
Michele BASTIDE
KMKouach Mostafa
Kouach Mostafa
SGSophie Gautier
Sophie Gautier
RBRégis Bordet
Régis Bordet

1 August 2007 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
MBMichele BASTIDE
Michele BASTIDE
TOT. Ouk
T. Ouk
FPF. Plaisier
F. Plaisier
OPO. Pétrault
O. Pétrault
SSS. Stolc
S. Stolc
RBR. Bordet
R. Bordet